Name: Remdesivir cuts COVID-19 death risk by 62%, drugmaker says
Brand: upi.com
SKU: upi-com-424
Availability: OnlineOnly

critic

Remdesivir cuts COVID-19 death risk by 62%, drugmaker says

preview

TrendingAdvertisementOne Gilead study showed Friday that a large share of pediatric and female patients had recovered after 28 days of remdesivir treatment. File photo by Terry Schmitt/UPI |The antiviral drug remdesivir has demonstrated that it can lower the risk of death in patients, U.S. drugmaker Gilead Sciences reported in new data Friday.Calling the finding "important," Gilead released the data in a virtual event that's part of the 23rd International AIDS Conference.AdvertisementAccording to the data, remdesivir minimizes the risk of death by 62 percent in patients with the coronavirus, compared with standard care alone.Gilead said the results came from a comparative analysis among 312 patients in its Phase 3 "SIMPLE-Severe" remdesivir clinical trial. Patients receiving the drug were compared to a "real-world" cohort of 818 COVID-19 patients with similar characteristics and disease severity who received only standard care.A separate analysis looking at the effect of remdesivir across racial and ethnic groups found that traditionally marginalized groups recorded "similar clinical outcomes" as the overall patient population in the study.A third analysis showed that 83 percent of pediatric patients and 92 percent of pregnant and postpartum women with varying COVID-19 severity had recovered after 28 days of remdesivir treatment."These data ... shed additional light on the use of remdesivir in specific patient populations, including those that may be susceptible to higher rates of COVID-19 infection, as well as others that are particularly vulnerable," Gilead Chief Medical Officer Merdad Parsey in a statement.AdvertisementThe drug, an antiviral developed to treat viruses like Ebola, was shown to be at least somewhat effective against COVID-19 in a study by the National Institute of Allergy and Infectious Diseases. The following month, the granted the drug emergency use authorization to fight COVID-19.Gilead says it has an agreement with the Department of Health and Human Services to control allocations of remdesivir to hospitals nationwide through September.Visitors wear face masks as they tour the Whitney Museum of American Art as it reopens on September 3. Photo by John Angelillo/UPI |AdvertisementAdvertisementAdvertisement

TrendingAdvertisementOne Gilead study showed Friday that a large share of pediatric and female patients had recovered after 28 days of remdesivir treatment. File photo by Terry Schmitt/UPI |The antiviral drug remdesivir has demonstrated that it can lower the risk of death in patients, U.S. drugmaker Gilead Sciences reported in new data Friday.Calling the finding "important," Gilead released the data in a virtual event that's part of the 23rd International AIDS Conference.AdvertisementAccording to the data, remdesivir minimizes the risk of death by 62 percent in patients with the...

public

Don Jacobson

upi.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

Remdesivir cuts COVID-19 death risk by 62%, drugmaker says

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS